Merkel Cell Carcinoma Analysis of Outcomes: A 30-Year Experience.
Merkel Cell Carcinoma Analysis of Outcomes: A 30-Year Experience.
复制标题
DOI：
10.1371/journal.pone.0129476
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Kimple RJ
中科院分区：
文献类型：
--
作者：
Liang E;Brower JV;Rice SR;Buehler DG;Saha S;Kimple RJ
Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with poor prognosis. Limited data exists to guide treatment decisions. Here we report on our institutional experience and outcomes treating patients with MCC. A database search (1984-2014) of patients treated at the University of Wisconsin Hospital and Clinics was used to identify patients with histologically confirmed MCC. Patient, tumor, and treatment characteristics were examined via review of medical records. Statistical analyses were performed to assess outcomes and associated prognostic factors. A total of 87 patients with MCC were identified with a median follow-up of 17 months (mean: 38, range: 0-210 months). Two and five-year overall survival rates were 53.9% and 32.8%, respectively. Recurrence was documented in 31.0% of patients (85.2% locoregional, 48.1% distant and 33.3% both). Patients with a history of immunosuppression exhibited significantly worse survival (hazard ratio, 2.01; 95% CI, 1.1-3.7) when compared to immune-competent individuals. The head and neck region was the most common location of primary lesion (N=49) followed by the extremities (N=31). Upper extremity primaries predicted significantly better overall survival (hazard ratio, 0.48; 95% CI, 0.23-0.99) while lower extremity primaries did not have significantly better results (hazard ratio, 0.5; 95% CI, 0.21-1.2) in comparison to head and neck site of primary. Nodal involvement (hazard ratio, 2.95; 95% CI, 1.5-5.79) was also a negative prognostic factor associated with poor overall survival when compared with clinically node negative patients. Primary tumor size > 2 cm (hazard ratio, 1.76; 95% CI, 0.91-3.4) was not associated with survival. This study highlights the role of various factors in determining prognosis of Merkel cell carcinoma; history of immunosuppression, nodal involvement, and head/neck primary predicted worse overall survival. These findings suggest that improvements in both distant and locoregionally directed therapies might play an important role in control of MCC and identify areas for future study.
登录
查看更多内容
影响因子：
6.2
作者：
Fields, Ryan C.;Busam, Klaus J.;Coit, Daniel G.
通讯作者：
Coit, Daniel G.
影响因子：
10.9
作者：
Asgari, Maryam M.;Sokil, Monica M.;Nghiem, Paul
通讯作者：
Nghiem, Paul
影响因子：
168.9
作者：
Engels, EA;Frisch, M;Miller, RW
通讯作者：
Miller, RW
影响因子：
10.3
作者：
Kaae, Jeanette;Hansen, Anne V.;Melbye, Mads
通讯作者：
Melbye, Mads
影响因子：
9
作者：
Fields, Ryan C.;Busam, Klaus J.;Coit, Daniel G.
通讯作者：
Coit, Daniel G.